Ironwood Pharmaceuticals | IRWD - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Almirall EUR 531.16M 13.76M 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amarin USD 51.48M 113K 2025-12
Ardelyx USD 127.27M 7.15M 2026-03
Astellas Pharma JPY 455.56B 33.8B 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Charles River Laboratories USD 2.84B 1.96B 2026-06
Coherus Biosciences USD 51.83M 2.48M 2025-12
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Incyte USD 973.64M 4.65B 2026-06
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
MacroGenics USD 42.87M 21.68M 2026-06
Moderna USD 960M 817M 2026-06
Myriad Genetics USD 212.8M 16.2M 2025-12
Pacira USD 180.54M 7.79M 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Takeda JPY 1.02T 89.68B 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12